Treatment of primary osteoporosis in men - Test2 - elhamkhani - TriplyDB

Treatment of primary osteoporosis in men

Treatment of primary osteoporosis in men

http://www.wikidata.org/entity/Q26991748

about

Management of endocrine disease: Secondary osteoporosis: pathophysiology and management Effects of weight training time on bone mineral density of patients with secondary osteoporosis after hemiplegia.Oxytocin reverses osteoporosis in a sex-dependent manner.Persistence with denosumab and persistence with oral bisphosphonates for the treatment of postmenopausal osteoporosis: a retrospective, observational study, and a meta-analysis Comparative Efficacy of Bisphosphonates to Prevent Fracture in Men with Osteoporosis: A Systematic Review with Network Meta-Analyses.The relationship between osteoporosis and body composition in pre- and postmenopausal women from different ethnic groups in China.Use of Zoledronic Acid in Paediatric Craniofacial Fibrous Dysplasia.Mechanical basis of bone strength: influence of bone material, bone structure and muscle action Restoration of osteogenic differentiation by overexpression of cannabinoid receptor 2 in bone marrow mesenchymal stem cells isolated from osteoporotic patients.

P2860

Q26998249-16AB790E-32D0-41BC-AD7E-E0FB95DFEAEC Q33598172-774A98DE-E68C-455F-8E5D-4C391F4E1B2A Q35622627-FE4A19F9-B868-4423-A7C1-D987174B9BCE Q36073645-2569E7B7-5FA1-4880-B651-6C0E6B834954 Q37208464-FA747258-EC32-4558-88F2-53002B80A9DE Q40527795-CB3BEC09-CC5A-41F4-B90C-DCE9C4020B03 Q41376322-681C3181-3E0F-425E-837A-3B68A85819CC Q41707116-431ABCD7-FAA9-4ABC-AD11-5B2EDA22658D Q47110612-755AA428-5033-4DCE-87E1-4CE949A9A434

P2860

Treatment of primary osteoporosis in men

http://www.wikidata.org/entity/Q26991748

description

2014 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

name

Treatment of primary osteoporosis in men

@ast

Treatment of primary osteoporosis in men

@en

Treatment of primary osteoporosis in men

@nl

type

label

Treatment of primary osteoporosis in men

@ast

Treatment of primary osteoporosis in men

@en

Treatment of primary osteoporosis in men

@nl

prefLabel

Treatment of primary osteoporosis in men

@ast

Treatment of primary osteoporosis in men

@en

Treatment of primary osteoporosis in men

@nl

P1433

Q26991748-A4E8EDA3-0C9D-4ED3-9835-88EBB91839F6

P1476

Q26991748-026D2E3B-C394-42CA-B876-EF89970D1F00

P2093

Q26991748-0611DBD6-3855-4A44-A652-9910BEF5001A

Q26991748-5B963DD1-4FDD-43A1-8052-3FAD00DA8E19

P275

Q26991748-F3217FDD-61CC-4EE5-9B34-AC1A7FFF611F

P2860

Q26991748-00D2750F-3C5B-4368-9B1A-7280FDF09EC2

Q26991748-057A8069-B842-4E6F-B5E5-1C742BEB35B1

Q26991748-0AE1AF9A-9AAB-447C-A3DF-2026A32940BA

Q26991748-0BD2878F-5623-406C-A279-F88FF6198F09

Q26991748-0C581220-A594-4B55-8F30-FBADE612713A

Q26991748-0CBB6046-EA08-4750-9F28-6E4A4166DBC1

Q26991748-116A35EB-521A-4D5E-BC59-A080AF07CC3E

Q26991748-2048D3A6-50E5-4FC9-9A56-9CF7D91A7A1D

Q26991748-24BD3C56-EBB9-409F-85C4-8760F3336F38

Q26991748-2549B463-497F-447B-93A1-4E9642474F2D

P304

Q26991748-C60EA04C-3591-4496-93D5-D6B4ED6E30B1

P31

Q26991748-2DF8EFCE-825A-4DC3-B548-B2C6BA5C9908

Q26991748-3C3473D8-575E-4693-916A-041BB6254753

P3181

Q26991748-C0043858-31CD-4BA1-AF1A-A226B02EEA9D

P356

Q26991748-DCDD187C-A97B-441D-87CA-9F617DD09CF3

P407

Q26991748-367807E3-8A11-4029-AD8D-FCCA1C38EFCA

P478

Q26991748-CF2F95DF-DC05-493A-A7E5-25428FD46D90

P5008

Q26991748-4F643BE2-C5C8-4245-AF2B-928A697C60A4

P577

Q26991748-5DD51578-A43E-4542-AA0C-0310C688968C

Q26991748-EED257C0-6BB1-4B7F-A807-B006421AAFFB

P698

Q26991748-8CBE5830-C7D1-416D-8B07-01CC36A3A401

P921

Q26991748-93ED6501-ACED-4A5E-BE6B-2071BF5DC191

P932

Q26991748-AE962BEB-CA23-4501-BA82-197E05E7123F

P3181

P356

P1433

Clinical Interventions in Aging

P1476

Treatment of primary osteoporosis in men

@en

P2093

Andrea Giusti

http://www.w3.org/2001/XMLSchema#string

Geralamo Bianchi

http://www.w3.org/2001/XMLSchema#string

P275

Creative Commons Attribution-NonCommercial

P2860

Does alendronate reduce the risk of fracture in men? A meta-analysis incorporating prior knowledge of anti-fracture efficacy in women

The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis

Denosumab for prevention of fractures in postmenopausal women with osteoporosis

Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis

Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group.

Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: Treatment of Peripheral Osteoporosis (TROPOS) study.

Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis.

Osteoporosis prevention, diagnosis, and therapy.

The effect of three or six years of denosumab exposure in women with postmenopausal osteoporosis: results from the FREEDOM extension

Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group.

P304

105-15

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

2129527

http://www.w3.org/2001/XMLSchema#string

P356

10.2147/CIA.S44057

http://www.w3.org/2001/XMLSchema#string

P407

P478

10

http://www.w3.org/2001/XMLSchema#string

P5008

P577

2014-12-30T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

2015-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25565793

http://www.w3.org/2001/XMLSchema#string

P921

P932

4283986

http://www.w3.org/2001/XMLSchema#string